The FDA has approved a supplemental new drug application for Dextenza, adding ocular itching associated with allergic conjunctivitis to the drug’s current indications, according to a press release from Ocular Therapeutix.
“Allergic conjunctivitis is a common condition seen in the offices of eye care providers. We are really excited about this label expansion and the potential benefits for patients,” Michael Goldstein, MD, president, ophthalmology, and chief medical officer at Ocular Therapeutix, said in the release.
The new approval for Dextenza (dexamethasone ophthalmic